secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001213900-25-007521
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio treats first patient in Phase II portion of INKmune trial for metastatic prostate cancer at VA hospital
--------------------------------------------------------------------------------

- First patient treated in Phase II portion of Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC) at West LA VA Medical Center.
- Patient received the medium dose of INKmune, an NK cell therapy, expanding the ongoing trial to the VA health system.
- Approximately 15,000 Veterans diagnosed with prostate cancer annually; 200,000+ Veterans are survivors.
- Principal investigator Dr. Matthew Rettig notes the therapy is given as outpatient with minimal side effects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025007521/0001213900-25-007521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025007521/ea0228960-8k_inmunebio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-007521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer